Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Convalescent plasma AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
1,320 results
  • Consensus statement and recommendations on the treatment of COVID-19: 2021 update. [Journal Article]
    J Chin Med Assoc. 2021 Sep 03 [Online ahead of print]Ko HK, Yu WK, … Research Center for Epidemic Prevention - National Yang Ming Chiao Tung University (RCEP-NYCU)
  • Many treatments including antiviral and non-antiviral drugs, and critical care are considered for the management of coronavirus disease 2019 (COVID-19). Practice recommendations need to be updated and graded according to critical evaluation of rapidly emerging literature. In June 2020, Research Center for Epidemic Prevention - National Yang Ming Chiao Tung University formed a task group comprisin…
  • Hypothesis: Immunotherapy by Selective Convalescent Blood Engineering to Stifle Diseases like COVID-19. [Review]
    Int J Med Sci. 2021; 18(15):3389-3394.Mukherjee AP
  • Current standard vaccine testing protocols take approximately 10-24 months of testing before a vaccine can be declared successful. Sometimes by the time a successful vaccine is out for public use, the outbreak may already be over. With no vaccine or antiviral drug available to treat the infected, we are left with the age-old methods of isolation, quarantine, and rest, to arrest such a viral outbr…
  • Application of extracorporeal therapies in critically ill COVID-19 patients. [Journal Article]
    J Zhejiang Univ Sci B. 2021 Sept 15; 22(9):701-717.Zhou Z, Kuang H, … Zhang L
  • The coronavirus disease 2019 (COVID-19) pandemic is a major public health event caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread widely all over the world. A high proportion of patients become severely or critically ill, and suffer high mortality due to respiratory failure and multiple organ dysfunction. Therefore, providing timely and effective treatmen…
  • X-Linked Agammaglobulinemia and COVID-19: Two Case Reports and Review of Literature. [Journal Article]
    Pediatr Allergy Immunol Pulmonol. 2021 09; 34(3):115-118.Devassikutty FM, Jain A, … Govindaraj GM
  • Introduction: The Centers for Disease Control and Prevention (CDC) has listed primary immunodeficiency disorders as being predisposed to severe coronavirus disease 2019 (COVID-19). However, patients affected with X-linked agammaglobulinemia (XLA) have shown contrary results. In this study, we present 2 boys in late adolescence from south India with XLA who were infected with severe acute respirat…
  • Why Does the Precautionary Principle Suffice for Blood Regulation? [Journal Article]
    Pharmaceut Med. 2021 Sep 07 [Online ahead of print]Seifner A, Fox AW
  • Traditional approaches to blood regulation emphasise the precautionary principle and pursue zero-risk for viral transmission; these traditional approaches have usually followed tragedy, such as the HIV and hepatitis C infections that followed the use of factor VIII concentrates. However, a much more haphazard haemovigilance system operates for general adverse events. Such imprecise assessment of …
  • The Convalescent Plasma Craze! Where Does India Stand? [Review]
    J Lab Physicians. 2021 Jun; 13(2):183-191.Priyadarsini AJ, Karan K, Arulselvi S
  • India becomes the country with second highest number of coronavirus disease 2019 (COVID-19) cases (59,03,932) as of September 2020. As the world debates various treatment options, the current pandemic has led to the resurgence of an ancient technique, namely convalescent plasma therapy. Although it has been in use from the late 19th century, it is an uncharted territory for most developing nation…
  • Development of ACE2 autoantibodies after SARS-CoV-2 infection. [Journal Article]
    PLoS One. 2021; 16(9):e0257016.Arthur JM, Forrest JC, … Harville TO
  • CONCLUSIONS: Many patients with a history of SARS-CoV-2 infection have antibodies specific for ACE2. Patients with ACE2 antibodies have lower activity of soluble ACE2 in plasma. Plasma from these patients also inhibits exogenous ACE2 activity. These findings are consistent with the hypothesis that ACE2 antibodies develop after SARS-CoV-2 infection and decrease ACE2 activity. This could lead to an increase in the abundance of Ang II, which causes a proinflammatory state that triggers symptoms of PASC.
  • Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. [Journal Article]
    J Infect Dis. 2021 09 01; 224(5):777-782.Kim MH, Salloum S, … MGH COVID-19 Collection & Processing Team
  • We analyzed plasma levels of interferons (IFNs) and cytokines, and expression of IFN-stimulated genes in peripheral blood mononuclear cells in patients with coronavirus disease 2019 of varying disease severity. Patients hospitalized with mild disease exhibited transient type I IFN responses, while intensive care unit patients had prolonged type I IFN responses. Type II IFN responses were compromi…
New Search Next